NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of KYTHERA Biopharmaceuticals, Inc. (“KYTHERA” or the “Company”) (NASDAQ:KYTH) concerning the proposed acquisition of the Company by Allergan plc (“Allergan”). Pursuant to the terms of the definitive merger agreement, KYTHERA stockholders will have the right to receive $75.00 in a combination of cash and shares of Allergan common stock for each share of Kythera common stock they own, in a transaction valued at approximately $2.1 billion.
The investigation concerns whether the KYTHERA Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values the Company’s common stock.
If you are a KYTHERA stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at firstname.lastname@example.org, or telephone at (212) 699-1145 or toll free at (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating in securities, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.